Abstract
The purpose of this investigation was to describe the characteristics of the use of systemic antifungal agents (AFAs) and to evaluate their appropriateness of use. A prospective drug-utilisation study was conducted in intensive-care areas: haematology-oncology services and transplant units. Data were collected in three periods over 9 months. The required sample size was determined to be 113 patients (margin of error ±7%, 95% confidence interval [CI]), assuming a variability of 50%. Two different investigator groups evaluated the appropriateness of use separately; Cohen’s Kappa index was used to calculate the degree of agreement between groups. A total of 114 patients we included, of which 62 (54.4%) were children. A total of 150 prescriptions were administered; fluconazole was the most frequently prescribed (38%), followed by liposomal amphotericin B (22.7%) and caspofungin (18.7%). The indications were: (1) pre-emptive treatment of Candida in non-neutropaenic critically ill patients (35.1%), (2) treatment of systemic fungal infection (24.6%), (3) prophylaxis for systemic fungal infection (SFI) in immunocompromised patients (16.7%), (4) prophylaxis of SFI in transplant recipients (12.3%), (5) prophylaxis of SFI in preterm infants (5.3%), (6) treatment of SFI in neonates (6.1%). The Kappa index showed a substantial agreement (Kappa = 0.73). The indications were considered to be inappropriate in 71 (47.3%) episodes. The indications or dosages were inappropriate in 79 cases (52.7%). The indications, dosages or duration of treatment were inappropriate in 83 cases (55.3%). We conclude that AFAs are prescribed for a significant number of inappropriate indications.
Similar content being viewed by others
References
Vartivarian SE, Anaissie EJ, Bodey GP (1993) Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis 17(suppl 2):S487–S491
Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546–1554
Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323–1332
Hadley S, Karchmer AW (1995) Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am 9:1045–1074
Wingard JR (1999) Fungal infections after bone marrow transplant. Biol Blood Marrow Transplant 5:55–68
Williamson EC, Millar MR, Steward CG, Cornish JM, Foot AB, Oakhill A, Pamphilon DH, Reeves B, Caul EO, Warnock DW, Marks DI (1999) Infections in adults undergoing unrelated donor bone marrow transplantation. Br J Haematol 104:560–568
Saiman L, Ludington E, Pfaller M, Rangel-Frausto S, Wiblin RT, Dawson J, Blumberg HM, Patterson JE, Rinaldi M, Edwards JE, Wenzel RP, Jarvis W (2000) Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 19:319–324
Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP; National Epidemiology of Mycoses Survey (NEMIS) Study Group (2001) Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 33:177–186
Antinori S, Nebuloni M, Magni C, Fasan M, Adorni F, Viola A, Corbellino M, Galli M, Vago G, Parravicini C, Ridolfo AL (2009) Trends in the postmortem diagnosis of opportunistic invasive fungal infections in patients with AIDS: a retrospective study of 1,630 autopsies performed between 1984 and 2002. Am J Clin Pathol 132(2):221–227
Chandrasekar PH, Alangaden G, Manavathu E (2000) Aspergillus: an increasing problem in tertiary care hospitals? Clin Infect Dis 30:984–985
Dixon S, McKeen E, Tabberer M, Paisley S (2004) Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature. Pharmacoeconomics 22(7):421–433
de With K, Steib-Bauert M, Knoth H, Dörje F, Strehl E, Rothe U, Maier L, Kern WV (2005) Hospital use of systemic antifungal drugs. BMC Clin Pharmacol 5(1):1
Alonso S, Arribi A, Vergas J, Martín MC, Arce B, Terleira A, Portolés A (2009) Estudio piloto de utilización de antifúngicos sistémicos en el Hospital Clínico San Carlos. Propuesta de un método de estúdio. Rev Esp Quimioter 22(3):127–134
Modified Karch–Lasagna algorithm. Spanish Pharmacovigilance System. In: Aguirre, C. Causalidad en Farmacovigilancia. In: Rodríguez, J.M., Aguirre, C. (Eds.) Pharmacovigilancia. Bibao: Servicio Editorial de la Universidad del País Vasco, pp 93–98
Meunier F, Lukan C (2008) The First European Conference on Infections in Leukaemia—ECIL1: a current perspective. Eur J Cancer 44:2112–2117
Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik J-A, Wingard JR, Patterson TF; Infectious Diseases Society of America (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327–360
Cornely OA, Böhme A, Buchheidt D, Einsele H, Heinz WJ, Karthaus M, Krause SW, Krüger W, Maschmeyer G, Penack O, Ritter J, Ruhnke M, Sandherr M, Sieniawski M, Vehreschild JJ, Wolf HH, Ullmann AJ (2009) Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 94(1):113–122
Rowe JM, Ciobanu N, Ascensao J, Stadtmauer EA, Weiner RS, Schenkein DP, McGlave P, Lazarus HM (1994) Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the Eastern Cooperative Oncology Group (ECOG). Ann Intern Med 120(2):143–158
Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD; Infectious Diseases Society of America (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious Diseases Society of America. Clin Infect Dis 48:503–535
León C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Álvarez-Lerma F, Garnacho-Montero J, León MA; EPCAN Study Group (2006) A bedside scoring system (“Candida score”) for early antifungal treatment in non-neutropenic critically ill patients with Candida colonization. Crit Care Med 34(3):730–737
Protocolo de diagnóstico y tratamiento de infección fúngica invasora en pacientes críticos en UCI. Hospital Universitario 12 de Octubre. Madrid. Versión 1. Septiembre 2007
Almirante B, Rodríguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, Mensa J, Sanchez F, Ayats J, Gimenez M, Saballs P, Fridkin SK, Morgan J, Rodriguez-Tudela JL, Warnock DW, Pahissa A; Barcelona Candidemia Project Study Group (2005) Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 43:1829–1835
Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA, Phelan M, Morgan J, Lee-Yang W, Ciblak MA, Benjamin LE, Sanza LT, Huie S, Yeo SF, Brandt ME, Warnock DW (2004) Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 42(4):1519–1527
Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D (2003) Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37:1172–1177
Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt LA, Pfaller MA (2002) Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 40:1298–1302
Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S (1997) The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 24:1122–1128
Slotman GJ, Burchard KW (1987) Ketoconazole prevents Candida sepsis in critically ill surgical patients. Arch Surg 122(2):147–151
Nguyen MH, Peacock JE Jr, Tanner DC, Morris AJ, Nguyen ML, Snydman DR, Wagener MM, Yu VL (1995) Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 155:2429–2435
Vincent JL, Anaissie E, Bruining H, Demajo W, el-Ebiary M, Haber J, Hiramatsu Y, Nitenberg G, Nyström PO, Pittet D, Rogers T, Sandven P, Sganga G, Schaller MD, Solomkin J (1998) Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 24(3):206–216
Prieto Yerro C, Laredo Velasco L, Rodríguez Bernardino Á, Vargas Castrillón E, Ambit Ávila MI, Merchante Medina A (2001) Modificación en el patrón de uso de anfotericina B no convencional tras la puesta en marcha de una intervención formativa en el Hospital Clínico San Carlos de Madrid. Rev Esp Salud Pública 75:353–360
Powers JH, Dixon CA, Goldberger MJ (2002) Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever. N Engl J Med 346:289–290
Garey KW, Pai MP, Suda KJ, Turpin RS, Rege MD, Mingo DE, Bearden DT (2007) Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf 16:919–927
White MH (1997) The contribution of fluconazole to the changing epidemiology of invasive candidal infections. Clin Infect Dis 24:1129–1130
Vehreschild JJ, Böhme A, Buchheidt D, Arenz D, Harnischmacher U, Heussel CP, Ullmann AJ, Mousset S, Hummel M, Frommolt P, Wassmer G, Drzisga I, Cornely OA (2007) A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 55:445–449
Playford EG, Webster AC, Sorrell TC, Craig JC (2004) Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev (3):CD004291
Winston DJ, Busuttil RW (2002) Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 74(5):688–695
Cai CJ, Yi SH, Guo Y, Li MR, Yi HM, Yang Y, Lu MQ, Chen GH (2007) The impact of itraconazole versus fluconazole on the prevention of postoperative invasive fungal infections after orthotopic liver transplantation. Zhonghua Nei Ke Za Zhi 46(11):911–913
Playford EG, Webster AC, Sorrell TC, Craig JC (2006) Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 25(9):549–561
Castroagudín JF, Pontón C, Bustamante M, Otero E, Martínez J, Tomé S, Conde R, Segade FR, Delgado M, Brage A, Galbán C, Varo E (2005) Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients. Transplant Proc 37(9):3965–3967
Clerihew L, McGuire W (2004) Systemic antifungal drugs for invasive fungal infection in preterm infants. Cochrane Database Syst Rev (1):CD003953
Austin NC, Darlow B (2004) Prophylactic oral antifungal agents to prevent systemic Candida infection in preterm infants. Cochrane Database Syst Rev (1):CD003478
Manzoni P, Arisio R, Mostert M, Leonessa M, Farina D, Latino MA, Gomirato G (2006) Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study. Paediatrics 117(1):e22–e32
Wade KC, Wu D, Kaufman DA, Ward RM, Benjamin DK Jr, Sullivan JE, Ramey N, Jayaraman B, Hoppu K, Adamson PC, Gastonguay MR, Barrett JS; National Institute of Child Health and Development Pediatric Pharmacology Research Unit Network (2008) Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother 52(11):4043–4049
Juster-Reicher A, Leibovitz E, Linder N, Amitay M, Flidel-Rimon O, Even-Tov S, Mogilner B, Barzilai A (2000) Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection 28:223–226
Yang BH, Peng MY, Hou SJ, Sun JR, Lee SY, Lu JJ (2009) Fluconazole-resistant Kodamaea ohmeri fungemia associated with cellulitis: case report and review of the literature. Int J Infect Dis 13(6):e493–e497
World Health Organization (WHO) (2003) Introduction to drug utilization research. WHO, Geneva
Meyer E, Schwab F, Gastmeier P, Ruden H, Heininger A (2007) Antifungal use in intensive care units. J Antimicrob Chemother 60(3):619–624
Cars O, Ekdahl K (2002) SWEDRES 2002. A report on Swedish antibiotic utilisation and resistance in human medicine. The Swedish Strategic Programme for the Rational Use of Antimicrobial Agents (STRAMA) and the Swedish Institute for Infectious Disease Control, Stockholm, pp 1–36
Grau S, Torres-Rodríguez JM, Monterde J (1996) Situación actual de las infecciones por hongos: ¿Son las anfotericinas lipídicas la panacea? Farm Hosp 20:390–392
Ericsson O, Hallmen AC, Wikstrom I (1996) Amphotericin B is incompatible with lipid emulsions. Ann Pharmacother 30:298
Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA; Micafungin Invasive Candidiasis Working Group (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369(9572):1519–1527
Rex JH, Lozano-Chiu M, Paetznik V and co-investigaors of the NIAID MSG Candidiasis Subproject (1998) Susceptibility testing of current Candida bloodstream isolates from Mycoses Study Group (MSG) Collaborative Study #34: isolates of C. krusei are often resistant to both fluconazole and amphotericin B [abstract 324]. In: Program and abstract of 36th Annual Meeting of Infectious Diseases Society of America (Denver): 136
European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) (2008) EUCAST technical Note on fluconazole. Clin Microbiol Infect 14:193–195
Nucci M (2003) Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 16:607–612
Voriconazole Spanish summary of product characteristics (available at: https://sinaem4.agemed.es/consaem/fichasTecnicas.do?metodo=detalleForm&version=new, last accessed September 28, 2010)
Marty FM, Cosimi LA, Baden LR (2004) Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 350:950–952
Zonios DI, Bennett JE (2008) Update on azole antifungals. Semin Respir Crit Care Med 29(2):198–210
Cook PP, Catrou PG, Christie JD, Young PD, Polk RE (2004) Reduction in broad-spectrum antimicrobial use associated with no improvement in hospital antibiogram. J Antimicrob Chemother 53:853–859
Acknowledgements
None to declare.
Funding
The study was carried out as part of the routine work of the Pharmacy Commission of the Hospital Universitario La Paz.
Conflicts of interest
Dr. Julio García-Rodríguez has been an advisor for Gilead Sciences, has received grant support from Gilead Sciences and Pfizer, has received travel grants from Merck Sharp & Dohme (MSD), Gilead Sciences, Pfizer and Astellas, and has served as a speaker to Pfizer, MSD and Astellas.
All other authors: none to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ramírez, E., García-Rodríguez, J., Borobia, A.M. et al. Use of antifungal agents in pediatric and adult high-risk areas. Eur J Clin Microbiol Infect Dis 31, 337–347 (2012). https://doi.org/10.1007/s10096-011-1315-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-011-1315-x